Analysts have upgraded Aclaris Therapeutics' revenue forecasts, leading to a 21% rise in share price. Despite expecting a decline in sales in 2025, analysts are more optimistic, reducing loss estimates.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing